Catalyst Corp (CPRX) - P/E multiplikatori
Catalyst Pharmaceuticals kompaniyasi AQSHda generik dori vositalariga qarshi qonuniy himoyadan foydalangan holda, kam uchraydigan kasalliklar dorilari nishasini egallab turibdi. Kompaniyaning maqsadli P/E ko'rsatkichi aktivning qiymatini haqiqiy daromadlar bilan nisbatan baholashga yordam beradi, bunda 17.60 qiymati ushbu metrikani aks ettiradi. Asosiy dori vositasiga berilgan patentlar barqaror pul oqimini ta'minlaydi. Mijozlar bazasining o'sishi va yangi dori vositalarining kengayishi barqaror talabni kafolatlaydi.
Catalyst Pharmaceuticals Inc (CPRX) kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning xususiy kapitalga nisbati Catalyst Pharmaceuticals|CPRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Catalyst Corp|CPRX - Kompaniya qarzlari|Sof aktivlarga qarzlar Catalyst Pharmaceuticals, Inc.|CPRX - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori Catalyst Pharmaceuticals|Oraliq qoplash koeffitsiyenti catalystpharma.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
CPRX - Kompaniyaning sof foydasi|Forvard foyda Catalyst Pharmaceuticals|CPRX - P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori Catalyst Pharma|CPRX - PEG multiplikatori|EV/EBITDA multiplikatori Catalyst Pharmaceuticals, Inc.|CPRX - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|Sirpanuvchi yil uchun bir aksiya uchun foyda Catalyst Pharmaceuticals|CPRX - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi catalystpharma.com|CPRX - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Catalyst Pharmaceuticals
Kompaniyaning har tomonlama tahlili:Catalyst Pharmaceuticals
GMP shartnomalari orqali ishlab chiqarishni autsorsing qilish modelidan foydalanadigan Catalyst Pharmaceuticals (CPRX) uchun P/E koeffitsiyenti sof foydaga nisbatan tashqi xarajatlarni boshqarish samaradorligining ko'rsatkichi bo'lib xizmat qiladi. Catalyst Pharmaceuticals ning oylik P/E dinamikasini tahlil qilish orqali investor bir dollar foydaning bozor qiymatini aniqlaydi hamda uchinchi tomon zavodlarining xarajatlari oshishi natijasida haddan tashqari ko'p to'lov qilish xavfini yoki marjaning pasayishi belgilarini taniydi.
Raqobatdosh kompaniyalar
Narx-foyda koeffitsiyenti biogen.com (BIIB)|P/E multiplikatori NBIX|P/E multiplikatori Regencell Bioscience Ltd (RGC)|Axsome Therapeutics Inc - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati ACAD (ACADIA Corp)|Xenon Pharmaceuticals - P/E multiplikatori|VKTX - P/E multiplikatori|Supernus (SUPN) - Narxning foydaga nisbati|DNLI (Denali) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti HRMY|Kapitalizatsiyaning foydaga nisbati Biohaven Corp BHVN|Narxning foydaga nisbati Amylyx Pharmaceuticals (AMLX)|Biznesning o‘zini qoplash muddati trevitherapeutics.com|Praxis Precision Medicines, Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati AVXL (Anavex)|CBLL: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PRTA (Prothena Corporation)|alector.com (ALEC) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati ANNX (annexonbio.com)|OMER (Omeros Corp) - P/E multiplikatori|NGNE: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ACIU|P/E multiplikatori Voyager Corp (VYGR)|Narxning foydaga nisbati Neumora Therapeutics NMRA|Kompaniya qiymatining sof foydaga nisbati SCLX|TVGN - Narxning foydaga nisbati|Alpha Cognition (ACOG) - Narx-foyda koeffitsiyenti|CGTX: P/E multiplikatori|Inhibikase Pharma (IKT) - P/E multiplikatori|SAVA (Cassava Sciences, Inc.) - P/E multiplikatori|Narx-foyda koeffitsiyenti Assertio Therapeutics (ASRT)|P/E multiplikatori COYA|VTGN - Kapitalizatsiyaning foydaga nisbati|Ovid Therapeutics - Narx-foyda koeffitsiyenti|P/E multiplikatori Acumen Pharmaceuticals, Inc ABOS|CRVO: Narx-foyda koeffitsiyenti|Alterity Therapeutics - Bozor narxining sof foydaga nisbati|CLNN: P/E multiplikatori|PEPG - Biznesning o‘zini qoplash muddati|JUNS (Jupiter Neurosciences) - P/E multiplikatori|Narx-foyda koeffitsiyenti Relmada Corp (RLMD)|P/E multiplikatori ANVS|P/E multiplikatori gracetx.com (GRCE)|Narxning foydaga nisbati Firefly Neuroscience AIFF|ANEW Medical - Narxning foydaga nisbati|NRSN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Reviva Pharmaceuticals, Inc. RVPH|MTVA: P/E multiplikatori|Narx-foyda koeffitsiyenti neuraxis.com|Narxning foydaga nisbati Helius Medical Technologies, Inc.|Passage Bio Corp - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva) - Kompaniya qiymatining sof foydaga nisbati|Athira Pharma, Inc. - Narx-foyda koeffitsiyenti|ADXN: Narx-foyda multiplikatori|ALZN - Narxning foydaga nisbati|CYCN (Cyclerion Therapeutics) - Narx-foyda multiplikatori|PTIX: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Pasithea Therapeutics Corp. (KTTA)|Narx-foyda koeffitsiyenti CRGT|P/E multiplikatori avenuetx.com|Narxning foydaga nisbati BrainStorm Cell Therapeutics (BCLI)|CARA (Cara Therapeutics Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Chromocell Therapeutics Corporation CHRO|Eliem Therapeutics, Inc. (ELYM) - Kapitalizatsiyaning foydaga nisbati|Intra-Cellular - P/E multiplikatori|longboardpharma.com (LBPH) - Narx-foyda koeffitsiyenti|MRNS: P/E multiplikatori|NKGen Biotech Inc (NKGN) - P/E multiplikatori|Narx-foyda koeffitsiyenti NRBO|SAGE (Sage Therapeutics Inc) - Bozor narxining sof foydaga nisbati|P/E multiplikatori SNPX|P/E multiplikatori trevena.com (TRVN)|Narxning foydaga nisbati Vigil Neuroscience, Inc. VIGL|anewmeds.com - Narxning foydaga nisbati|CERE: Narx-foyda koeffitsiyenti
